Company Description
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners, and alternate sites of care worldwide.
It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments.
The company offers dental merchandise, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, and PPE products; dental equipment, such as dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair; and branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, and vitamins.
It also provides financial services on a nonrecourse basis, education services for practitioners, consulting, and other services; and consumable merchandise under its own brand.
In addition, the company manufactures, markets, and sells dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other health care-related products and services.
Further, it is involved in the development and distribution of practice management software, e-services, and other products to health care providers.
The company serves customers in dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics and other alternate care clinics.
Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
| Country | United States |
| Founded | 1932 |
| IPO Date | Nov 3, 1995 |
| Industry | Medical Distribution |
| Sector | Healthcare |
| Employees | 25,000 |
| CEO | Stanley Bergman |
Contact Details
Address: 135 Duryea Road Melville, New York 11747 United States | |
| Phone | 631 843 5500 |
| Website | henryschein.com |
Stock Details
| Ticker Symbol | HSIC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001000228 |
| CUSIP Number | 806407102 |
| ISIN Number | US8064071025 |
| Employer ID | 11-3136595 |
| SIC Code | 5047 |
Key Executives
| Name | Position |
|---|---|
| Ronald N. South | Senior Vice President and Chief Financial Officer |
| Michael Saul Ettinger | Executive Vice President and Chief Operating Officer |
| Mark E. Mlotek | Executive Vice President, Chief Strategic Officer and Executive Director |
| Olga Timoshkina | Vice President of Corporate Finance, Chief Accounting Officer and Corporate Controller |
| Christopher Pendergast | Senior Vice President and Chief Technology Officer |
| Graham Stanley | Vice President of Investor Relations and Strategic Finance Project Officer |
| Walter Siegel | Senior Vice President and Chief Legal Officer |
| Christine Sheehy | Senior Vice President and Chief Human Resources Officer |
| Mark Hillebrandt | Vice President and Chief Data Revenue Officer |
| James Mullins | Senior Vice President of Global Supply Chain |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2025 | SCHEDULE 13D/A | Filing |
| May 5, 2025 | 10-Q | Quarterly Report |
| May 5, 2025 | 8-K | Current Report |
| May 2, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 2, 2025 | 8-K | Current Report |
| Apr 25, 2025 | SCHEDULE 13G | Filing |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Apr 15, 2025 | 8-K | Current Report |
| Apr 9, 2025 | ARS | Filing |
| Apr 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |